CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells That Constitutively Secrete Interleukin 18 (19-28z/IL-18) in Patients With Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06287528
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:27.516910+00:00
Published At: 2026-02-10T00:00:00+00:00
Record Updated At: 2026-02-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Philadelphia-Negative ALL", "Philadelphia-Positive ALL", "Relapsed ALL, Adult", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Lymphoblastic Leukemia (ALL)", "Refractory Acute Lymphoid Leukemia in Relapse"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-10"
protocolSection.identificationModule.nctId: "NCT06287528"
protocolSection.identificationModule.officialTitle: "A Phase I Trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells That Constitutively Secrete Interleukin 18 (19-28z/IL-18) in Patients With Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.